Millennium reports 5.8% Tenax Therapeutics stake
TENAX THERAPEUTICS, INC.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
TENAX THERAPEUTICS, INC. (TENX) received a Schedule 13G reporting a significant ownership position by Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander. These reporting persons disclose beneficial ownership of 2,156,891 shares of Tenax Therapeutics common stock, representing 5.8% of the outstanding class. They report no sole voting or dispositive power over the shares, but shared voting and shared dispositive power over the same 2,156,891 shares. The shares are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC and Mr. Englander. The filing states that this structure should not, by itself, be construed as an admission by any of the reporting persons of beneficial ownership of the securities held by those entities.
Key Figures
Key Terms
Schedule 13G regulatory
beneficially owned financial
dispositive power financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of TENX does Millennium Management report owning in this Schedule 13G?
Who are the reporting persons on the TENX Schedule 13G filed in August 2026?
Where are the main Millennium entities in the TENX Schedule 13G organized and based?
AI-generated analysis. How Rhea-AI works. Not financial advice.